What's new

Human medicines European public assessment report (EPAR): Uplizna, inebilizumab, Date of authorisation: 25/04/2022, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Uplizna, inebilizumab, Date of authorisation: 25/04/2022, Revision: 6, Status: Authorised

Mar 27, 2025 - 14:37
 0
Human medicines European public assessment report (EPAR): Uplizna, inebilizumab, Date of authorisation: 25/04/2022, Revision: 6, Status: Authorised
Human medicines European public assessment report (EPAR): Uplizna, inebilizumab, Date of authorisation: 25/04/2022, Revision: 6, Status: Authorised
Read More

Tags:

Previous Article

Car makers brace for huge financial impact of Trump tariffs

Next Article

Turkey’s Aselsan receives $616 million investment for Steel Dome-related tech fa...

Related Posts

Human medicines European public assessment report (EPAR): Kinpeygo, budesonide, Date of authorisation: 15/07/2022, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 11, 2025  0

Orphan designation: Tafasitamab Treatment of follicular lymphoma, 26/02/2025 Positive

Orphan designation: Tafasitamab Treatment of follicular...

Mar 11, 2025  0

Human medicines European public assessment report (EPAR): Pemetrexed Accord, pemetrexed, Date of authorisation: 18/01/2016, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 12, 2025  0